DENVAX: Targeting mechanical immune memory to optimize human dendritic cell vaccines
Description of the granted funding
Immunotherapy is the most important new form of cancer therapy and is currently revolutionizing cancer treatment. In immunotherapy, the aim is to increase the functionality of the patients own immune system to attack tumors. One example of cancer immunotherapy is cell therapy, where the patient's own immune cells are utilized as cancer therapeutics. Dendritic cell therapies (vaccines) are one such treatment modality. Although dendritic cell vaccines are safe and well tolerated, their clinical efficacy is not very impressive. Dendritic cell vaccines therefore clearly need further development. In this project, we will investigate whether dendritic cell vaccines can be optimized by modifying dendritic cell function in different ways. We utilize human dendritic cell cultures (vaccines) in our research. Our ultimate aim is to develop new types of dendritic cell vaccines that are more efficient towards tumors than current therapies.
Show moreStarting year
2025
End year
2026
Granted funding
Funder
Research Council of Finland
Funding instrument
Targeted Academy projects
Decision maker
Suomen akatemian muu päättäjä
28.11.2024
28.11.2024
Other information
Funding decision number
365203
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
cancer